European Commission approves the second indication of isatuximab for relapsed multiple myelomaAccess, MyelomaApril 19, 2021
Selinexor receives Conditional Marketing Authorisation in Europe for the treatment of relapsed and or refractory myeloma patientsAccess, MyelomaMarch 30, 2021
The FDA approves melphalan flufenamide for patients with relapsed or refractory myelomaAccess, MyelomaMarch 1, 2021
FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patientsAccess, MyelomaMay 14, 2020
The European Medicines Agency (EMA) recommends extension of indications for daratumumabAccess, MyelomaOctober 21, 2019
European Commission approves elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory myelomaAccess, MyelomaAugust 28, 2019
Janssen seeks European marketing authorisation for subcutaneous (under the skin) daratumumab (Darzalex®)Access, MyelomaJuly 19, 2019
Lenalidomide and pomalidomide based triplet combination regimens for myeloma patients receives approval from the European CommissionAccess, MyelomaMay 23, 2019